test

Responsive

test

test

Other35.39%

Cochlear Investments Pty Ltd17.88%

Coöperatieve Gilde Healthcare III Sub-Holding U.A. and Coöperatieve Gilde Healthcare III Sub-Holding 2 U.A14.29%

Robert Taub + MINV SA12.76%

TOGETHER Partnership11.34%

Jürgen Hambrecht4.74%

ResMed Inc.3.6%


Voting Rights

Total number of voting rights (denominator)

22,097,609

(all relating to ordinary shares)

Total number of securities carrying voting rights

22,097,609

(all relating to ordinary shares)

Total number of securities carrying voting rights not yet issued

1,007,500

(all related to 2013 ESOP warrants, 2016 ESOP warrants, 2018 ESOP warrants and 2021 ESOP warrants)

test

test

test

Questions?
Visit the FAQ

Frequently asked questions
about the Genio® system

FAQ

All rights reserved © 2021 Nyxoah SA. All content on this presentation, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design etc., are the property of Nyxoah SA. Nyxoah SA. owns all rights with respect to any of their trademarks, service marks, logos, and copyrighted works appearing on this presentation. Patented and design protected technology. Device not for sale in U.S. The Genio® system by Nyxoah is intended to be used for patients who suffer from moderate to severe Obstructive Sleep Apnea (AHI of 15 to 65), have not tolerated, failed or refused PAP therapy and are not significantly overweight. Reviewed and approved: February 2020

bubble
bubble
bubble
bubble
bubble